clopidogrel has been researched along with Asthma, Bronchial in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cazzola, M; Hanania, NA; Matera, MG; Rogliani, P | 1 |
| Choi, Y; Nguyen, TVT; Park, HS; Shin, YS; Suh, DH; Trinh, HKT | 1 |
| Burroughs, T; Dykewicz, MS; Jenkins, P; Lobb, A; O'Rourke, D; Shaker, M; Sheth, S; Takemoto, SK | 1 |
4 other study(ies) available for clopidogrel and Asthma, Bronchial
| Article | Year |
|---|---|
Cardiovascular disease in asthma patients: From mechanisms to therapeutic implications.
Topics: Asthma; Cardiovascular Diseases; Clopidogrel; Comorbidity; Humans; Ticagrelor | 2023 |
Characterization of cysteinyl leukotriene-related receptors and their interactions in a mouse model of asthma.
Topics: Acetates; Animals; Asthma; Clopidogrel; Cyclohexanecarboxylic Acids; Cyclopropanes; Disease Models, Animal; Drug Therapy, Combination; Eosinophils; Female; Inflammation; Interleukins; Leukotriene Antagonists; Mice; Mice, Inbred BALB C; Ovalbumin; Phthalic Acids; Purinergic P2Y Receptor Antagonists; Quinolines; Receptors, Leukotriene; Receptors, Purinergic P2Y12; Sulfides; Th2 Cells | 2019 |
[Proton pump inhibition: more than only reflux therapy].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Asthma; Chest Pain; Clopidogrel; Comorbidity; Controlled Clinical Trials as Topic; Coronary Disease; Diagnosis, Differential; Drug Therapy, Combination; Gastroesophageal Reflux; Humans; Omeprazole; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Proton Pump Inhibitors; Rabeprazole; Secondary Prevention; Ticlopidine; Time Factors | 2008 |
An economic analysis of aspirin desensitization in aspirin-exacerbated respiratory disease.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Asthma; Cardiovascular Diseases; Clopidogrel; Cost-Benefit Analysis; Desensitization, Immunologic; Drug Hypersensitivity; Humans; Markov Chains; Middle Aged; Models, Biological; Platelet Aggregation Inhibitors; Quality-Adjusted Life Years; Respiration Disorders; Ticlopidine | 2008 |